icon-folder.gif   Conference Reports for NATAP  
 
  DDW - Digestive Disease Week 2014
May 4, 2014, Chicago
Illinois, United States
Back grey_arrow_rt.gif
 
 
 
PEARL-IV: A 12-week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves SVR12 Rates ≥90% in Treatment-na´ve Adults Infected With Hepatitis C Virus Genotype 1a
 
 
  Download the PDF here
 
Reported by Jules Levin
DDW - Digestive Disease Week 2014, May 4, 2014, Chicago, Illinois, United States
 
David Bernstein1, Jacob Lalezari2, Yan Luo3, Terry D Box4, Ziad H Younes5, Bal Raj Bhandari6, Thomas Sepe7, Curti s Cooper8, Ed Tam9, Naoky Tsai10, Tarek Hassanein11, Wangang Xie3, Thomas Podsadecki3
1North Shore University Hospital, Manhasset, New York, United States; 2Quest Clinical Research, San Francisco, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Clinical Research Centers of America, Murray, Utah, United States; 5GastroOne, Germantown, Tennessee, United States; 6Delta Research Partners, LLC, Bastrop, Louisiana, United States;
7University Gastroenterology, Providence, Rhode Island, United States; 8University of Ott awa, Ott awa, Ontario, Canada; 9LAIR Centre, Vancouver, Canada; 10The Queen's Medical Center - Liver Center, Honolulu, Hawaii, United States; 11Southern California Liver Centers and Southern California Research Center, Coronado, California, United States
 
Yesterday this study was reported in the NEJM along with PEARL III (gt1b) in the same publication, pdf attached.
 
Gt1b - EASL: PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-na´ve HCV Genotype 1b-Infected Adults With or Without Ribavirin - (04/16/14)
 
Phase 3 - EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
 
Phase 3 - EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NA´VE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
 
Phase 3 - EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
 
Gt4 - EASL: RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - (04/16/14)

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

HCV9.gif

HCV10.gif

HCV11.gif